Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Blood (2025) 146 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2025-4232

Published: 2025

Journal Articles

Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT

Nico Gagelmann, Kyle Hebert, Thomas McGovern, Gabrielle Schmidt, Valerie Stewart, Donna Neuberg, Stephen Spellman, Jeffery Auletta, Steven Devine, Robert Soiffer, Immaculata De Vivo, Christopher Reilly, R. Coleman Lindsley

Blood (2025) 146 (Supplement 1): 373.

https://doi.org/10.1182/blood-2025-373

Published: 2025

Journal Articles

Impact of HLA alloimmunization on availability of HLA well matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation

Brian Shaffer, Amanda Blouin, Candice Rapoport, Deborah Wells, Stephanie Chinapen, Miguel-Angel Perales, Steven Devine, Jeffery Auletta, Heather Stefanski, Stephen Spellman, Martin Maiers

Blood (2025) 146 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2025-2434

Published: 2025

Journal Articles

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Blood (2025) 146 (Supplement 1): 936.

https://doi.org/10.1182/blood-2025-936

Published: 2025

Journal Articles

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Blood (2025) 146 (Supplement 1): 1058.

https://doi.org/10.1182/blood-2025-1058

Published: 2025

Journal Articles

Vδ2 unconventional T cells in the donor graft are associated with improved overall survival after unrelated donor allo-HCT for AML and MDS: An analysis from the DKMS and NMDP graft composition study

Blood (2025) 146 (Supplement 1): 1057.

https://doi.org/10.1182/blood-2025-1057

Published: 2025

Journal Articles

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Anna Desalvo, Brittany Ragon, Neel Bhatt, Betty K. Hamilton, Azra Borogovac, Mary Horowitz, Nandita Khera, Mark Juckett, Steven Devine, Christopher Dandoy, Alla Keyzner, Yvonne Efebera, John Plastaras, Mitchell Horwitz, Sarah Wall, Valerie Stewart, Mykala Heuer, Todd Molfenter

Blood (2025) 146 (Supplement 1): 7913.

https://doi.org/10.1182/blood-2025-7913

Published: 2025

Journal Articles

Living the recovery: One-year qol outcomes for patients receiving ptcy gvhd prophylaxis on the access clinical trial

Rachel Cusatis, Jianqun Kou, Juan (Maggie) Wu, Caitrin Bupp, Deborah Mattila, Sarah Smith, Kathryn Flynn, Jeffery Auletta, Steven Devine, Brent Logan, Bronwen Shaw

Blood (2025) 146 (Supplement 1): 6042.

https://doi.org/10.1182/blood-2025-6042

Published: 2025

Journal Articles

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Kai Yu, Laura Dillon, Jesse Tettero, Gege Gui, Rasha Al-Ali, Michael Grunwald, Elizabeth Krakow, Elizabeth Griffiths, Alexandra Gomez-Arteaga, Rahul Vedula, Melhem Solh, Amandeep Salhotra, Nelli Bejanyan, Lori Muffly, Antonio Jimenez-Jimenez, Michael Drazer, Yi-Bin Chen, Aaron Logan, Reena Jayani-Kosarzycki, Sophia Balderman, James Blachly, Brian Shaffer, Marc Schwartz, Cecilia Yeung, Lawrence Druhan, Vanessa Kennedy, Sandeep Gurbuxani, Melissa Tjota, Max Smith, Farah Sahoo, Dylan Barfield, Jim Guo, James Han, Jason Hu, Heejoon Jo, Vidya Kudlingar, Wilfred Li, Yutong Qiu, Pratheesh Sathyan, Sean Truong, Severine Catreux, Sam Ng, Khai Luong, Yunjiao Zhu, Reem Bahr, Jamie Diemer, Jianqun Kou, Stephanie Bo-Subait, Jackie Bjerke, Steven Devine, Bergetta Dietel, Christina Ferrone, Gabrielle Giammarino, Emily Heying, Emily Kolb, Danielle O'Donnell Vitali, Wael Saber, Stephen Spellman, Brenna Tesch, Jenny Vogel, Stephanie Waldvogel, Syreeta Weatherspoon, Jeffery Auletta, Christopher Hourigan

Blood (2025) 146 (Supplement 1): 455.

https://doi.org/10.1182/blood-2025-455

Published: 2025

Journal Articles

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Blood (2025) 146 (Supplement 1): 170.

https://doi.org/10.1182/blood-2025-170

Published: 2025

Journal Articles

ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation

Sarah Smith, Heather Stefanski, Stephen Spellman, Joseph Stanek, Dillon Corrigan, Brent Logan, Bronwen Shaw, Rachel Cusatis, Erin Leckrone, Jeffery Auletta, Steven Devine

Blood (2025) 146 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2025-6035

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Blood (2024) 143 (1): 21–31.

https://doi.org/10.1182/blood.2023020250

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Blood (2022) 139 (24): 3546–3557.

https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant

Blood (2021) 138 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2021-153312

Published: 2021

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans

Rajshekhar Chakraborty, Lisa A. Rybicki, Jaime M. Preussler, Steven Devine, K. Scott Baker, Karen Syrjala, Jean C. Yi, Jennifer L Whitten, Bronwen E. Shaw, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 431.

https://doi.org/10.1182/blood-2021-149281

Published: 2021

Journal Articles

Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients

Zeina Al-Mansour, Sanghee Hong, Nosha Farhadfar, Jing Zhao, Ji-Hyun Lee, Bronwen E. Shaw, Steven Devine, Jean C. Yi, Jaime M. Preussler, K. Scott Baker, Karen Syrjala, Navneet S. Majhail, John R. Wingard

Blood (2021) 138 (Supplement 1): 426.

https://doi.org/10.1182/blood-2021-151037

Published: 2021

Journal Articles

Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program

Heather E. Stefanski, Jeni Newman, Jennifer Novakovich, Jacklyn Barten, Jason Oakes, Meghann Cody, Huy P Pham, Jeffery Auletta, John P. Miller, Steven Devine

Blood (2021) 138 (Supplement 1): 478.

https://doi.org/10.1182/blood-2021-152952

Published: 2021

Journal Articles

Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors

Sanghee Hong, Jing Zhao, Ji-Hyun Lee, Nosha Farhadfar, Jean C. Yi, Jaime M. Preussler, K. Scott Baker, Bronwen E. Shaw, Steven Devine, Karen Syrjala, John R. Wingard, Navneet S. Majhail, Zeina Al-Mansour

Blood (2021) 138 (Supplement 1): 4123.

https://doi.org/10.1182/blood-2021-145428

Published: 2021

Journal Articles

Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association

Blood (2021) 138 (Supplement 1): 3887.

https://doi.org/10.1182/blood-2021-150013

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT

Impact of HLA alloimmunization on availability of HLA well matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Vδ2 unconventional T cells in the donor graft are associated with improved overall survival after unrelated donor allo-HCT for AML and MDS: An analysis from the DKMS and NMDP graft composition study

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Living the recovery: One-year qol outcomes for patients receiving ptcy gvhd prophylaxis on the access clinical trial

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans

Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients

Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program

Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors

Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only